Table 2 Stasis Box lead molecules
MMV ID | CHEMBL ID | Name(s) | Indication | Mechanism of action | Target |
|---|---|---|---|---|---|
MMV690732 | CHEMBL3545403 | XL-139; BMS-833923 | Cancer | Smoothened homolog antagonist | Smoothened homolog |
MMV690596 | CHEMBL1836102 | CGP-71683 | Obesity, eating disorder | Neuropeptide receptor antagonist | na |
MMV003452 | CHEMBL15928 | GR-127935 | Depression | 5-HT 1B/1D receptor antagonist | 5-HT 1B and 5-HT 1D receptors |
MMV690599 | CHEMBL88272 | RS-17053 | Prostate hyperplasia | Alpha 1 adrenoreceptor antagonist | na |
MMV690466 | CHEMBL59030 | GW-3965 | Inflammation, melanoma | Agonist of LXR receptor | na |
MMV690787 | CHEMBL513909 | BI-2536 | Cancer | Serine/threonine-protein kinase PLK1 inhibitor | Serine/threonine-protein kinase PLK1 |
MMV690684 | CHEMBL91867 | CL-387785 | Cancer | Epidermal growth factor receptor (EGFR) receptor antagonist + Tyrosine Kinase (TK) inhibitor | na |
MMV690646 | CHEMBL2111096 | CK0238273; SB-715992-S; Ispinesib | Cancer | Kinesin inhibitor | KIF11 |
MMV690765 | CHEMBL607707 | EKB-569; Pelitinib | Cancer | EGFR erbB1 inhibitor | EGFR erbB1 |
MMV690534 | CHEMBL238125 | SD-208 | Cancer, chronic pulmonary obstruction | TGFb TK inhibitor + receptor antagonist | na |
MMV001539 | CHEMBL16687 | CGS-15943 | Ischemia, stroke | Adenosine A2 receptor antagonist | na |